Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

United Community Banks Inc (UCB)

United Community Banks Inc (UCB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,769,470
  • Shares Outstanding, K 119,287
  • Annual Sales, $ 1,313 M
  • Annual Income, $ 187,540 K
  • EBIT $ 280 M
  • EBITDA $ 325 M
  • 60-Month Beta 0.92
  • Price/Sales 2.82
  • Price/Cash Flow 12.32
  • Price/Book 1.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.56
  • Number of Estimates 4
  • High Estimate 0.59
  • Low Estimate 0.53
  • Prior Year 0.53
  • Growth Rate Est. (year over year) +5.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.89 +2.30%
on 12/18/24
35.38 -10.68%
on 11/25/24
-0.89 (-2.74%)
since 11/20/24
3-Month
26.00 +21.54%
on 10/23/24
35.38 -10.68%
on 11/25/24
+2.06 (+6.97%)
since 09/20/24
52-Week
24.04 +31.45%
on 06/17/24
35.38 -10.68%
on 11/25/24
+2.36 (+8.07%)
since 12/20/23

Most Recent Stories

More News
United Community Banks, Inc. to Acquire ANB Holdings, Inc. in $80 Million All-Stock Merger

United Community Banks, Inc. will acquire ANB Holdings, Inc. in an $80 million all-stock transaction, enhancing Miami market presence.Quiver AI SummaryUnited Community Banks, Inc. and ANB Holdings, Inc....

UCB : 31.60 (+1.77%)
United Community Banks, Inc. and ANB Holdings, Inc., the Parent of American National Bank, Announce Merger Agreement

UCB : 31.60 (+1.77%)
United Community Banks, Inc. Announces Quarterly Cash Dividend Approval

United Community Banks approved a quarterly cash dividend of $0.24 per share, payable January 6, 2025.Quiver AI SummaryUnited Community Banks, Inc. has announced the approval of a quarterly cash dividend...

UCB : 31.60 (+1.77%)
United Community Banks, Inc. Announces Quarterly Cash Dividend on Common and Preferred Stock

UCB : 31.60 (+1.77%)
United Community Banks: Q3 Earnings Snapshot

United Community Banks: Q3 Earnings Snapshot

UCB : 31.60 (+1.77%)
United Community Banks, Inc. Reports Third Quarter Results

UCB : 31.60 (+1.77%)
UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis

FDA approval of ZILBRYSQ® (zilucoplan) has been granted for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine...

UCB : 31.60 (+1.77%)
UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

FDA approval of RYSTIGGO® (rozanolixizumab-noli) has been granted under the Priority Review designation for the treatment of generalized myasthenia gravis...

UCB : 31.60 (+1.77%)
UCB and Ariceum Therapeutics sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer

/PRNewswire/ -- Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain...

UCB : 31.60 (+1.77%)
UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

/PRNewswire/ -- UCB (Euronext: UCB), a global biopharmaceutical company, today announced the U.S. Drug Enforcement Administration (DEA) has published a final...

UCB : 31.60 (+1.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

United Community Bank is a bank holding company. United conducts its operations through a community-focused operating model of separate community banks, which, as of December 31, 2016, operated at 139 locations throughout the Atlanta-Sandy Springs-Roswell, Georgia, and Gainesville, Georgia metropolitan...

See More

Key Turning Points

3rd Resistance Point 33.19
2nd Resistance Point 32.60
1st Resistance Point 32.10
Last Price 31.60
1st Support Level 31.01
2nd Support Level 30.42
3rd Support Level 29.92

See More

52-Week High 35.38
Last Price 31.60
Fibonacci 61.8% 31.05
Fibonacci 50% 29.71
Fibonacci 38.2% 28.37
52-Week Low 24.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar